Back to News
Market Impact: 0.35
Alnylam Pharmaceuticals Q3 Earnings Call Highlights
Source: marketbeat.com
Corporate EarningsHealthcare & BiotechCompany Fundamentals
Alnylam Pharmaceuticals reported approximately $1.3 billion in global net product revenue for third-quarter 2026, up 52% year over year and 10% sequentially. The company attributed continued growth to its transthyretin (TTR) franchise.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
ALNY0.70
More News
- DoorDash offers $17 billion for Instacart: ‘the largest companies are only eating more and more of the pie’
- Alphabet Erases $500 Billion as ChatGPT, Google AI Cut into Search
- Alphabet just had its worst day as a public company. BofA now values Google search at a lower multiple than fossil fuel stocks
- Norwegian shares surge 13% on earnings beat, guidance raise
- Taiwan Stocks Heads for Correction as Global AI Selloff Deepens
- Asia stocks tumble as AI spending concerns deepen; BOJ holds rates